CTOs on the Move

TLC Laser Eye Centers

www.tlcvision.com

 
TLC Laser Eye Centers is North America’s leading laser eye surgery provider, with more than 20 years of LASIK experience. Book a Free Consultation near you.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tlcvision.com
  • 5280, Solar Drive
    Mississauga, ON CAN L4W 5M8
  • Phone: 877.852.2020

Executives

Name Title Contact Details

Similar Companies

Meyer Pharmaceuticals (Main)

Meyer Pharmaceuticals (Main) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CerpassRx

CerpassRx is dedicated to giving you the best online pharmacy experience possible. Contact us today to get your pharmacy benefit management.

Regulatory Applications and Strategy Consulting

Regulatory Applications and Strategy Consulting is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phlexglobal

Phlexglobal is the leading technology and services organization for clinical and regulatory matters with a focus on helping clients to master their digital agenda via proven AI solutions. Phlexglobal combines software and leading expert services to offer a unique solutions portfolio with easy to achieve automation via data generation that lifts organizations to a new level of effectiveness. PhlexTMF, the company`s Trial Master File software, and Regulatory Solutions including PhlexSubmission for eCTD and CTD, PhlexIDMP, PhlexEVMPD, and PhlexRIM are considered highly innovative in the industry for their out of the box best practices capabilities, use of automation technology, and user-focused design. PhlexNeuron, a machine learning platform that reads documents and converts unstructured content into structured data, achieves automation of regulatory and clinical processes and completes the end to end solutions offering from Phlexglobal. Phlexglobal is a PharmaLex Group company. The PharmaLex Group now has over 2,300 employees, with 53 offices in 25 countries and more than 1,000 satisfied clients worldwide.

Seqirus

Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine, and supplies diagnostic reagents in the Australasia region. Seqirus cold-chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia.